| (Values in U.S. Thousands) | Mar, 2024 | Dec, 2023 | Sep, 2023 | Jun, 2023 | Mar, 2023 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -9,800 | -2,360 | 4,040 | -4,170 | -1,510 |
| Net Income Growth | -315.25% | -158.42% | +196.88% | -176.16% | +59.73% |
Mymd Pharmaceuticals Inc (MYMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
MyMD Pharmaceuticals Inc. is a clinical stage pharmaceutical company involved in developing therapeutic platforms. MyMD Pharmaceuticals Inc., formerly known as Akers Biosciences Inc., is based in Maryland.